This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tyrosinase
DrugBank Accession Number
DB16626
Background

Tyrosinase is a multi-copper-containing multifunctional metalloenzyme with 4 possible oxidation states.1,2,3 It is responsible for producing melanin pigment across the phylogenetic spectrum.1,2,3

Within mammals, tyrosinase is found specifically in melanocytes in a glycosylated form and plays a critical role in regulating the process of melanin biosynthesis (also known as melanogenesis).1,3 It is recognized as being the main enzyme responsible for enzymatic browning and melanogenesis in mammals, thus causing undesired browning of fruits and vegetables and diseases resulting from melanin overproduction.1

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Peptides
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Monophenol monooxygenase
  • Tumor rejection antigen AB
External IDs
  • Tyrosinase

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

During melanogenesis, tyrosinase acts as a rate-limiting enzyme.1

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
G2UX40NTG9
CAS number
9002-10-2

References

General References
  1. Zolghadri S, Bahrami A, Hassan Khan MT, Munoz-Munoz J, Garcia-Molina F, Garcia-Canovas F, Saboury AA: A comprehensive review on tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2019 Dec;34(1):279-309. doi: 10.1080/14756366.2018.1545767. [Article]
  2. Ramsden CA, Riley PA: Tyrosinase: the four oxidation states of the active site and their relevance to enzymatic activation, oxidation and inactivation. Bioorg Med Chem. 2014 Apr 15;22(8):2388-95. doi: 10.1016/j.bmc.2014.02.048. Epub 2014 Mar 4. [Article]
  3. Hearing VJ, Jimenez M: Mammalian tyrosinase--the critical regulatory control point in melanocyte pigmentation. Int J Biochem. 1987;19(12):1141-7. doi: 10.1016/0020-711x(87)90095-4. [Article]
Wikipedia
Tyrosinase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionIris Melanoma / Medium/Large Size Posterior Uveal Melanoma / Mucosal Melanoma / Ocular Melanoma With Extraocular Extension / Recurrent Melanoma / Recurrent Uveal Melanoma / Small Size Posterior Uveal Melanoma / Stage IIA Cutaneous Melanoma AJCC v6 and v7 / Stage IIA Uveal Melanoma AJCC v7 / Stage IIB Cutaneous Melanoma AJCC v6 and v7 / Stage IIB Uveal Melanoma AJCC v7 / Stage IIC Cutaneous Melanoma AJCC v6 and v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Uveal Melanoma AJCC v7 / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Uveal Melanoma AJCC v7 / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Uveal Melanoma AJCC v7 / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Uveal Melanoma AJCC v71
3TerminatedTreatmentIntraocular Melanoma1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Ciliary Body and Choroid Melanoma, Small Size / Extraocular Extension Melanoma / Iris Melanoma / Melanoma Stage Iv / Metastatic Intraocular Melanoma / Mucosal Melanoma / Recurrent Intraocular Melanoma / Recurrent Melanoma / Stage IIC Melanoma / Stage IIIA Intraocular Melanoma / Stage IIIA Melanoma / Stage IIIB Intraocular Melanoma / Stage IIIB Melanoma / Stage IIIC Intraocular Melanoma / Stage IIIc Melanoma / Stage IV Intraocular Melanoma1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Melanoma Stage Iv / Stage IIB Melanoma / Stage IIC Melanoma / Stage IIIA Melanoma / Stage IIIB Melanoma / Stage IIIc Melanoma1
2CompletedTreatmentIntraocular Melanoma / Melanoma4
2CompletedTreatmentMelanoma9
2CompletedTreatmentMelanoma Stage Iv / Recurrent Melanoma / Renal Cell Cancer, Recurrent / Stage IV Renal Cell Cancer1
2CompletedTreatmentMelanoma / Neoplasms, Metastasis1
2TerminatedTreatmentMelanoma1
2Unknown StatusTreatmentMetastatic Melanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at February 26, 2021 16:46 / Updated at March 18, 2021 22:45